Cost-benefit Analysis of Yindan Xintai Dropping Pills in the Treatment of Angina Pectoris Caused by Coro-nary Heart Disease
10.6039/j.issn.1001-0408.2016.05.01
- VernacularTitle:银丹心泰滴丸治疗冠心病心绞痛的成本-效益分析
- Author:
Hongyan WU
;
Lei TANG
- Publication Type:Journal Article
- Keywords:
Yindan xintai dropping pills;
Angina pectoris caused by coronary heart disease;
Cost-benefit analysis;
Contingent valuation method;
Net benefit;
Incremental net benefit
- From:
China Pharmacy
2016;27(5):577-580
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the economics of Yindan xintai dropping pills in the treatment of angina pectoris caused by coronary heart disease from societal perspectives. METHODS:Therapy regimens related to Yindan xintai dropping pills and con-trol regimens were selected from published literatures included in database,and the cost of therapy regimens and clinical effect data were extracted from literatures. Contingent evaluation method was used to measure people's willingness-to-pay for angina pectoris treatments. An econometric model was conducted to transfer the effectiveness data to benefit data. The economics of treatment was evaluated depending upon net benefit or incremental net benefit indicator. RESULTS & CONCLUSIONS:When Yindan xintai drop-ping pills is used alone,its net benefit is >0,indicating economical advantage;56 d therapy regimen is better than 28 d therapy. When Yindan xintai dropping pills were combined with glyceryl trinitrate tablet,Isosorbide mononitrate sustained-release tablet, Simvastatin dispersible tablet and other drugs,its incremental net benefit is better than control regimens and has good economics.
